A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Toprol Xl Side Effects, and Drug Interactions - Metoprolol Succinate
Toprol Xl Side Effects, and Drug Interactions - Metoprolol Succinate
SIDE EFFECTS
Hypertension and Angina
Most adverse effects have been mild and transient. The following
adverse reactions have been reported for metoprolol tartrate.
Central Nervous System: Tiredness and dizziness
have occurred in about 10 of 100 patients. Depression has been reported
in about 5 of 100 patients. Mental confusion
and short-term memory loss
have been reported. Headache, somnolence, nightmares, and insomnia
have also been reported.
Cardiovascular: Shortness of breath
and bradycardia
have occurred in approximately 3 of 100 patients. Cold extremities;
arterial insufficiency, usually of the Raynaud type; palpitations;
congestive heart failure; peripheral
edema; syncope; chest
pain; and hypotension
have been reported in about 1 of 100 patients (see CONTRAINDICATIONS,
WARNINGS, and PRECAUTIONS).
Respiratory: Wheezing (bronchospasm) and dyspnea
have been reported in about 1 of 100 patients (see WARNINGS).
Gastrointestinal: Diarrhea has occurred in about
5 of 100 patients. Nausea, dry mouth, gastric
pain, constipation, flatulence, digestive tract
disorders and heartburn
have been reported in about 1 of 100 patients.
Hypersensitive Reactions: Pruritus or rash
have occurred in about 5 of 100 patients. Worsening or psoriasis
has also been reported.
Miscellaneous: Peyronie's disease
has been reported in fewer than 1 of 100,000 patients. Musculoskeletal
pain, blurred vision, decreased libido
and tinnitus have also
been reported.
There have been rare reports of reversible
alopecia, agranulocytosis, and dry eyes. Discontinuation of the
drug should be considered
if any such reaction is not otherwise explicable. The oculomucocutaneous
syndrome associated
with the beta-blocker practolol has not been reported with metoprolol.
Potential Adverse REACTIONS
A variety of adverse reactions not listed above have been reported
with other beta-adrenergic blocking
agents and should be considered potential adverse reactions to extended
release metoprolol succinate.
Central Nervous System: Reversible mental
depression progressing
to catatonia; an acute
reversible syndrome
characterized ny disorientation for time
and place, short-term memory loss, emotional lability, slightly
clouded sensorium, and decreased performance
on neuropsychometrics.
Cardiovascular: Intensification of AV block
(see CONTRAINDICATIONS.)
Hematologic: Agranulocytosis, nonthrombocytopenic
purpura, thrombocytopenic purpura.
Hypersensitive Reactions: Fever combined with aching
and sore throat, laryngospasm, and respiratory distress.
DRUG INTERACTIONS
Catecholamine-depleting drugs (e.g., reserpine) may have
an additive effect when given with beta-blocking agents. Patients
treated with extended release metoprolol succinate
plus a catecholamine
depletor should therefore be closely observed for evidence
of hypotension or
marked bradycardia, which may produce vertigo, syncope, or postural
hypotension.
top
